ZA963907B - Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereof - Google Patents
Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereofInfo
- Publication number
- ZA963907B ZA963907B ZA963907A ZA963907A ZA963907B ZA 963907 B ZA963907 B ZA 963907B ZA 963907 A ZA963907 A ZA 963907A ZA 963907 A ZA963907 A ZA 963907A ZA 963907 B ZA963907 B ZA 963907B
- Authority
- ZA
- South Africa
- Prior art keywords
- nucleic acid
- acid molecules
- mhc molecule
- form complexes
- molecule hla
- Prior art date
Links
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 102000025850 HLA-A2 Antigen Human genes 0.000 title 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 239000002243 precursor Substances 0.000 abstract 4
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/487,135 US5821122A (en) | 1995-06-07 | 1995-06-07 | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA963907B true ZA963907B (en) | 1997-03-11 |
Family
ID=23934549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA963907A ZA963907B (en) | 1995-06-07 | 1996-05-16 | Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (3) | US5821122A (es) |
EP (1) | EP0845032B1 (es) |
JP (1) | JP3849102B2 (es) |
AT (1) | ATE209680T1 (es) |
AU (1) | AU704934B2 (es) |
CA (1) | CA2223694C (es) |
DE (1) | DE69617440T2 (es) |
DK (1) | DK0845032T3 (es) |
ES (1) | ES2167561T3 (es) |
PT (1) | PT845032E (es) |
WO (1) | WO1996040039A2 (es) |
ZA (1) | ZA963907B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE402259T1 (de) | 1997-01-27 | 2008-08-15 | Ludwig Inst Cancer Res | Lage-1 tumor-assozierte nukleinsäuren |
US6680191B1 (en) | 1997-04-25 | 2004-01-20 | Ludwig Institute For Cancer | Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof |
US6734172B2 (en) | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
US20020164654A1 (en) * | 2000-01-20 | 2002-11-07 | Rosalie Luiten | MAGE antigenic peptides which bind HLA-B35 and HLA-B44 |
EP1188446B1 (en) | 2000-09-15 | 2009-08-05 | Institut Pasteur | Proteinaceous vectors for molecule delivery to CD11b expressing cells |
JP2004525620A (ja) | 2001-01-17 | 2004-08-26 | トルビオン・ファーマシューティカルズ・インコーポレイテッド | 結合ドメイン−免疫グロブリン融合タンパク質 |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US6607151B2 (en) * | 2001-08-16 | 2003-08-19 | Morris Samelson | Ultra fine dead sea mineral compound and method of manufacture |
JP4694128B2 (ja) | 2002-01-30 | 2011-06-08 | ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド | TIM−3、Th1特異的細胞表面分子に関連した組成物および方法 |
US20070026022A1 (en) * | 2004-11-19 | 2007-02-01 | Gilles Dadaglio | Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens |
DE602004024440D1 (de) * | 2003-11-21 | 2010-01-14 | Pasteur Institut | Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene |
KR20100092031A (ko) * | 2004-06-17 | 2010-08-19 | 맨카인드 코포레이션 | 에피토프 유사체 |
US8188243B2 (en) * | 2004-06-23 | 2012-05-29 | Board Of Regents Of The University Of Texas System | Methods and compositions for the detection of biological molecules using a two particle complex |
WO2010080909A1 (en) | 2009-01-08 | 2010-07-15 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
US20120171246A1 (en) | 2009-09-10 | 2012-07-05 | Yale University | Immunization to reduce neurotoxicity during treatment with cytolytic viruses |
WO2011056993A1 (en) | 2009-11-04 | 2011-05-12 | Yale University | Compositions and methods for treating cancer with attenuated oncolytic viruses |
CA2876209A1 (en) | 2012-06-15 | 2013-12-19 | Adaptive Biotechnologies Corporation | Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set |
SG10201707394PA (en) | 2013-03-15 | 2017-10-30 | Adaptive Biotechnologies Corp | Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set |
WO2015058111A1 (en) | 2013-10-17 | 2015-04-23 | The Brigham And Women's Hospital, Inc. | Cationic nanoparticles for co-delivery of nucleic acids and thereapeutic agents |
EP3721875B1 (en) | 2014-05-09 | 2023-11-08 | Yale University | Particles coated with hyperbranched polyglycerol and methods for their preparation |
US20180126014A1 (en) | 2015-04-15 | 2018-05-10 | Yale University | Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof |
WO2017095751A1 (en) | 2015-12-02 | 2017-06-08 | Partikula Llc | Compositions and methods for modulating cancer cell metabolism |
US20190117799A1 (en) | 2016-04-01 | 2019-04-25 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
EP3512563A1 (en) | 2016-09-16 | 2019-07-24 | The Johns Hopkins University | Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery |
US20200085758A1 (en) | 2016-12-16 | 2020-03-19 | The Brigham And Women's Hospital, Inc. | Co-delivery of nucleic acids for simultaneous suppression and expression of target genes |
EP3615052B1 (en) | 2017-04-27 | 2023-01-25 | The University of Hong Kong | Use of hcn inhibitors for treatment of cancer |
US11478433B2 (en) | 2017-06-23 | 2022-10-25 | Yale University | Nanomaterials with enhanced drug delivery efficiency |
WO2023010060A2 (en) | 2021-07-27 | 2023-02-02 | Novab, Inc. | Engineered vlrb antibodies with immune effector functions |
WO2023108076A1 (en) | 2021-12-08 | 2023-06-15 | Yale University | Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues |
WO2023147552A1 (en) | 2022-01-28 | 2023-08-03 | University Of Georgia Research Foundation, Inc. | Radiosensitizing compositions and methods of use thereof |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
WO2024112867A1 (en) | 2022-11-23 | 2024-05-30 | University Of Georgia Research Foundation, Inc. | Compositions and methods of use thereof for increasing immune responses |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
ES2172287T4 (es) * | 1992-12-22 | 2003-04-16 | Ludwig Inst Cancer Res | Metodos de deteccion y tratamiento de individuos con celulas anormales que expresan los antigenos peptidicos hla-a2/tirosinasa. |
US5620886A (en) * | 1993-03-18 | 1997-04-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
US5856091A (en) * | 1993-03-18 | 1999-01-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
US5554724A (en) * | 1994-03-24 | 1996-09-10 | University Of Leiden | Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof |
US5851523A (en) * | 1994-03-24 | 1998-12-22 | Ludwig Institute For Cancer Research. | Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof |
US5997870A (en) * | 1994-06-03 | 1999-12-07 | Ludwig Institute For Cancer Research | Isolated peptides which bind to HLA-B44 Molecules |
-
1995
- 1995-06-07 US US08/487,135 patent/US5821122A/en not_active Expired - Lifetime
-
1996
- 1996-05-07 CA CA002223694A patent/CA2223694C/en not_active Expired - Lifetime
- 1996-05-07 ES ES96913954T patent/ES2167561T3/es not_active Expired - Lifetime
- 1996-05-07 DK DK96913954T patent/DK0845032T3/da active
- 1996-05-07 WO PCT/US1996/006409 patent/WO1996040039A2/en active IP Right Grant
- 1996-05-07 PT PT96913954T patent/PT845032E/pt unknown
- 1996-05-07 AU AU56769/96A patent/AU704934B2/en not_active Expired
- 1996-05-07 AT AT96913954T patent/ATE209680T1/de active
- 1996-05-07 JP JP50052197A patent/JP3849102B2/ja not_active Expired - Lifetime
- 1996-05-07 EP EP96913954A patent/EP0845032B1/en not_active Expired - Lifetime
- 1996-05-07 DE DE69617440T patent/DE69617440T2/de not_active Expired - Lifetime
- 1996-05-16 ZA ZA963907A patent/ZA963907B/xx unknown
-
1997
- 1997-08-21 US US08/915,972 patent/US5886145A/en not_active Expired - Lifetime
-
1998
- 1998-10-23 US US09/177,909 patent/US5958711A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5821122A (en) | 1998-10-13 |
PT845032E (pt) | 2002-05-31 |
JP2001520506A (ja) | 2001-10-30 |
US5886145A (en) | 1999-03-23 |
DE69617440T2 (de) | 2002-08-08 |
EP0845032A4 (en) | 2000-05-10 |
CA2223694A1 (en) | 1996-12-19 |
AU5676996A (en) | 1996-12-30 |
US5958711A (en) | 1999-09-28 |
DE69617440D1 (de) | 2002-01-10 |
ATE209680T1 (de) | 2001-12-15 |
ES2167561T3 (es) | 2002-05-16 |
WO1996040039A3 (en) | 2000-03-23 |
AU704934B2 (en) | 1999-05-06 |
EP0845032A2 (en) | 1998-06-03 |
JP3849102B2 (ja) | 2006-11-22 |
DK0845032T3 (da) | 2002-05-06 |
EP0845032B1 (en) | 2001-11-28 |
CA2223694C (en) | 2003-06-24 |
WO1996040039A2 (en) | 1996-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA963907B (en) | Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereof | |
ZA944196B (en) | Isolated peptides which form complexes with MHC molecule HLA-C-clone 10 and uses thereof | |
ZA958039B (en) | Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof | |
DE69933998D1 (de) | Verbindungen und verfahren für therapie und diagnose von lungenkrebs | |
EP0690915A4 (en) | ISOLATED NUCLEIC ACID MOLECULES ENCODING THE MAGE-3 ANTI-TUMOR ANTIGEN PRECURSOR AND USES THEREOF | |
FI960268A (fi) | Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä | |
EA200101037A1 (ru) | Соединения и способы для лечения и диагностики рака легкого | |
NZ302821A (en) | isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors | |
NZ332369A (en) | Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof | |
ZA983488B (en) | Isolated nucleic acid molecule coding for tumor rejection antigen precursors mage-c1 and mage-c2 and uses thereof | |
CA2213001A1 (en) | Isolated nucleic acid molecule encoding peptides which form complexes with mhc molecule hla-cw*1601 and uses thereof | |
CA2165435A1 (en) | Isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof | |
TW372973B (en) | Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof | |
UA66753C2 (en) | Immunostimulator and method for its production |